Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Oncternal Therapeutics is a clinical-stage biopharmaceutical company developing innovative oncology therapies targeting unmet needs in prostate cancer and hematological malignancies. Its pipeline includes novel agents like ONCT-534, a dual-action androgen receptor inhibitor, and ROR1-targeted cell therapies and antibodies. The company focuses on precision medicine, leveraging unique mechanisms of action, and collaborates with academic and industry partners to advance cancer treatments.
This description was generated via AI from an annual report. Updated about 1 year ago.